Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Learn more about:
Related Clinical Trial
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum A Novel Therapeutic Treatment of Pyoderma Gangrenosum Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma by Injection Into the Affected Areas JAK-STAT Signaling Pathway in Pyoderma Gangrenosum A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Canakinumab for Pyoderma Gangrenosum A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Recruitment Information


Administrative Informations